{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:21:44Z","timestamp":1789932104045,"version":"4.0.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.autrev.2014.08.008","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T22:31:07Z","timestamp":1408746667000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et's disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Luca","family":"Cantarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Anelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Menicacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2014.08.008_bb0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.rdc.2013.02.010","article-title":"Beh\u00e7et's syndrome","volume":"39","author":"Hatemi","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2014.08.008_bb0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11926-010-0132-z","article-title":"Beh\u00e7et's syndrome","volume":"12","author":"Yazici","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2014.08.008_bb0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2009.10.005","article-title":"Etiopathogenesis of Beh\u00e7et's disease","volume":"9","author":"Mendoza-Pinto","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1034\/j.1399-0039.1999.540301.x","article-title":"Beh\u00e7et's disease, the silk road and HLA-B51: historical and geographical perspectives","volume":"54","author":"Verity","year":"1999","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.autrev.2014.08.008_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/08830189709116842","article-title":"The role of heat shock protein, microbial and autoimmune agents in the aetiology of Beh\u00e7et's disease","volume":"14","author":"Lehner","year":"1997","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Beh\u00e7et's disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0035","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","article-title":"Beh\u00e7et's disease: infectious aetiology, new autoantigens, and HLA-B51","volume":"60","author":"Direskeneli","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R\u2013IL12RB2 regions associated with Beh\u00e7et's disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2014.08.008_bb0045","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.624","article-title":"Genome-wide association studies identify IL23R\u2013IL12RB2 and IL10 as Beh\u00e7et's disease susceptibility loci","volume":"42","author":"Mizuki","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2014.08.008_bb0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","article-title":"Cytokines and Beh\u00e7et's disease","volume":"11","author":"Zhou","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0055","first-page":"1428","article-title":"Production of TNF-alpha and IL-1 in active Beh\u00e7et's disease","volume":"17","author":"Hamzaoui","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0060","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00296-005-0040-0","article-title":"Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Beh\u00e7et's disease. Does interleukin-1\u03b2 play a major role in Beh\u00e7et's synovitis?","volume":"27","author":"Pay","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2014.08.008_bb0065","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/rheumatology\/keg232R","article-title":"Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Beh\u00e7et's disease","volume":"42","author":"Karasneh","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.08.008_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00403-007-0794-1","article-title":"Relationship between periodontal findings and specific polymorphisms of interleukin-1alpha and -1beta in Turkish patients with Beh\u00e7et's disease","volume":"300","author":"Akman","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2014.08.008_bb0075","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/eji.201343353","article-title":"The purinergic P2\u00d77 receptor is expressed on monocytes in Beh\u00e7et's disease and is modulated by TNF-\u03b1","volume":"44","author":"Castrichini","year":"2014","journal-title":"Eur J Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.08.008_bb0080","first-page":"S53","article-title":"The lumps and bumps of Beh\u00e7et's syndrome","volume":"3","author":"Yazici","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12016-012-8319-x","article-title":"Beh\u00e7et syndrome: is it one condition?","volume":"43","author":"Yazici","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","article-title":"Beh\u00e7et's disease as an autoinflammatory disorder","volume":"4","author":"Gul","year":"2005","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"3 Suppl. 72","key":"10.1016\/j.autrev.2014.08.008_bb0095","first-page":"S115","article-title":"Successful use of canakinumab in a patient with resistant Beh\u00e7et's disease","volume":"30","author":"Cantarini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Beh\u00e7et's disease: a case series","author":"Cantarini","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000358125","article-title":"Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et's disease: a case series","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2014.08.008_bb0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.autrev.2012.07.023","article-title":"Recurrent pericarditis: autoimmune or autoinflammatory?","volume":"12","author":"Maestroni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.autrev.2011.10.008","article-title":"The fresco of autoinflammatory diseases from the pediatric perspective","volume":"11","author":"Rigante","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2012.07.020","article-title":"Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives","volume":"12","author":"Cantarini","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2012.07.015","article-title":"The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature","volume":"12","author":"Muscari","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.autrev.2009.11.021","article-title":"Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis","volume":"9","author":"Cantarini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2012.07.027","article-title":"Biologic drugs in autoinflammatory syndromes","volume":"12","author":"Caorsi","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0140","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's Disease","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.08.008_bb0145","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Houman","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0150","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0155","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0160","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.autrev.2014.05.003","article-title":"Immunotherapeutic strategies in autoimmune uveitis","volume":"13","author":"Papotto","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0165","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.autrev.2010.05.017","article-title":"Current therapeutic approaches to autoimmune chronic uveitis in children","volume":"9","author":"Simonini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0170","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3349\/ymj.2007.48.4.573","article-title":"Mucocutaneous lesions of Beh\u00e7et's disease","volume":"48","author":"Alpsoy","year":"2007","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.autrev.2014.08.008_bb0175","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000074113","article-title":"Review of the chronology of clinical manifestations in 60 patients with Beh\u00e7et's disease","volume":"207","author":"Alpsoy","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2014.08.008_bb0180","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1346-8138.1995.tb03947.x","article-title":"Prognosis and clinical relevance of recurrent oral ulceration in Beh\u00e7et's disease","volume":"22","author":"Bang","year":"1995","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0185","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.autrev.2014.01.006","article-title":"Diagnosis and classification of autoimmune uveitis","volume":"13","author":"Selmi","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0190","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaut.2009.02.011","article-title":"Beh\u00e7et's disease a contemporary review","volume":"32","author":"Mendes","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.08.008_bb0195","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ncprheum0436","article-title":"Beh\u00e7et's syndrome: disease manifestations, management, and advances in treatment","volume":"3","author":"Yazici","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0200","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","article-title":"Resistant Beh\u00e7et disease responsive to anakinra","volume":"149","author":"Botsios","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.08.008_bb0205","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/BF02235590","article-title":"Long-term clinical course and prognostic factors in intestinal Beh\u00e7et's disease","volume":"43","author":"Choi","year":"2000","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0210","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/ard.42.5.505","article-title":"The arthritis of Beh\u00e7et's disease: a prospective study","volume":"42","author":"Yurdakul","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0215","article-title":"Efficacy of anakinra in refractory Beh\u00e7et's disease sacroiliitis","author":"Caso","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0220","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.autrev.2010.07.011","article-title":"Biologics \u2014 beyond the joints","volume":"9","author":"Szekanecz","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1191\/0961203305lu2208oa","article-title":"Beh\u00e7et's disease and cardiovascular involvement","volume":"14","author":"Atzeni","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.08.008_bb0230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1536\/jhj.43.389","article-title":"Cardiovascular involvement in Beh\u00e7et's disease","volume":"43","author":"Gurgun","year":"2002","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.autrev.2014.08.008_bb0235","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jvs.2005.03.019","article-title":"Long-term outcome after surgical treatment of arterial lesions in Beh\u00e7et disease","volume":"42","author":"Hosaka","year":"2005","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.autrev.2014.08.008_bb0240","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0039-6060(97)90284-1","article-title":"Management of aneurysms in Beh\u00e7et's syndrome: an analysis of 24 patients","volume":"121","author":"Tuzun","year":"1997","journal-title":"Surgery"},{"key":"10.1016\/j.autrev.2014.08.008_bb0245","first-page":"152","article-title":"Abdominal aortic aneurysm in Beh\u00e7et's disease: new treatment options for an old and challenging problem","volume":"6","author":"Nitecki","year":"2004","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2014.08.008_bb0250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1148\/radiol.2203001418","article-title":"Aortic and arterial aneurysms in Beh\u00e7et disease: management with stent-grafts \u2014 initial experience","volume":"220","author":"Park","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.autrev.2014.08.008_bb0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1583\/1545-1550(2003)010<0075:ETCWIT>2.0.CO;2","article-title":"Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Beh\u00e7et's disease","volume":"10","author":"Kwon Koo","year":"2003","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.autrev.2014.08.008_bb0260","first-page":"2103","article-title":"Arterial lesions in Beh\u00e7et's disease. A study in 25 patients","volume":"22","author":"Le Thi Huong","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0265","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","article-title":"Clinical patterns of neurological involvement in Beh\u00e7et's disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group","volume":"122","author":"Akman-Demir","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2014.08.008_bb0270","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/jnnp.2006.093971","article-title":"Neurological symptoms of Adamantiades\u2013Beh\u00e7et's syndrome","volume":"77","author":"Pearce","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2014.08.008_bb0275","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10067-012-1953-0","article-title":"Vascular neurobehcet disease: correlation with current disease activity forum and systemic vascular involvement","volume":"31","author":"Mohammed","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0280","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1474-4422(09)70015-8","article-title":"Neuro-Beh\u00e7et's disease: epidemiology, clinical characteristics, and management","volume":"8","author":"Al-Araji","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0285","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00415-011-6319-z","article-title":"Atypical manifestations in Brazilian patients with neuro-Beh\u00e7et's disease","volume":"259","author":"Dutra","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0290","doi-asserted-by":"crossref","first-page":"107421","DOI":"10.1155\/2014\/107421","article-title":"Biological treatments in Beh\u00e7et's disease: beyond anti-TNF therapy","volume":"2014","author":"Caso","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2014.08.008_bb0295","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.008_bb0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0305","first-page":"cm1","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.autrev.2014.08.008_bb0310","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.clim.2013.04.008","article-title":"Inflammasome and cytokine blocking strategies in autoinflammatory disorders","volume":"147","author":"Moll","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0315","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.autrev.2014.01.056","article-title":"Biotherapies in Beh\u00e7et's disease","volume":"13","author":"Comarmond","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0320","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Beh\u00e7et's disease: an open-label pilot study","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3 Suppl. 77","key":"10.1016\/j.autrev.2014.08.008_bb0325","first-page":"152","article-title":"Anakinra for resistant Beh\u00e7et uveitis: why not?","volume":"31","author":"Emmi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0330","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","article-title":"Canakinumab in a patient with juvenile Beh\u00e7et's syndrome with refractory eye disease","volume":"71","author":"Ugurlu","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0335","first-page":"532","article-title":"Beh\u00e7et's disease: treatment of mucocutaneous lesions","volume":"23","author":"Alpsoy","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0340","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00296-009-1276-x","article-title":"Late response to anti-TNF-\u03b1 therapy in refractory mucocutaneous lesions of Beh\u00e7et's disease","volume":"31","author":"Aikawa","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2014.08.008_bb0345","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-014-2589-z","article-title":"Paradoxical mucocutaneous flare in a case of Beh\u00e7et's disease treated with tocilizumab","author":"Cantarini","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0350","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","article-title":"Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Beh\u00e7et's disease","volume":"29","author":"Bilginer","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"3 Suppl. 72","key":"10.1016\/j.autrev.2014.08.008_bb0355","first-page":"S80","article-title":"Beh\u00e7et's syndrome: a critical digest of the recent literature","volume":"30","author":"Hatemi","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0360","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of neuro-Beh\u00e7et's disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0365","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.autrev.2014.04.003","article-title":"Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease","volume":"13","author":"Olivieri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0370","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.mehy.2008.01.011","article-title":"Tocilizumab may be a potential addition to our weapons against neuro-Beh\u00e7et's disease","volume":"71","author":"Borhani Haghighi","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.autrev.2014.08.008_bb0375","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","article-title":"Tocilizumab treatment for neuro-Beh\u00e7et's disease, the first report","volume":"114","author":"Shapiro","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"3 Suppl. 72","key":"10.1016\/j.autrev.2014.08.008_bb0380","first-page":"S73","article-title":"Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report","volume":"30","author":"Urbaniak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0385","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/ket130","article-title":"Lack of efficacy of tocilizumab in mucocutaneous Beh\u00e7et's syndrome: report of two cases","volume":"52","author":"Diamantopoulos","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.08.008_bb0390","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0395","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et's disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0400","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","article-title":"Adalimumab for the treatment of Beh\u00e7et's disease: experience in 19 patients","volume":"51","author":"Perra","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.08.008_bb0405","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/s10165-010-0370-y","article-title":"Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero-Beh\u00e7et's disease","volume":"21","author":"Iwata","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0410","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis","volume":"110","author":"Joseph","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2014.08.008_bb0415","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","article-title":"Infliximab for patients with neuro-Beh\u00e7et's disease: case series and literature review","volume":"30","author":"Borhani Haghighi","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0420","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2014.08.008_bb0425","doi-asserted-by":"crossref","first-page":"193923","DOI":"10.1155\/2012\/193923","article-title":"Cellular and humoral mechanisms involved in the control of tuberculosis","volume":"2012","author":"Zu\u00f1iga","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0430","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Beh\u00e7et's disease \u2014 review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.08.008_bb0435","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/art.1780390704","article-title":"Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group","volume":"39","author":"Campion","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0440","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0445","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","article-title":"A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores","volume":"43","author":"Jiang","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0450","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0455","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0460","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0465","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0470","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0475","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/art.20277","article-title":"The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions","volume":"50","author":"Schiff","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0480","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"den Broeder","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0485","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0490","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/rheumatology\/ken223","article-title":"Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study","volume":"47","author":"Karanikolas","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2014.08.008_bb0495","first-page":"1538","article-title":"Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial","volume":"35","author":"Le Lo\u00ebt","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0500","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0505","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0510","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/rheumatology\/ken030","article-title":"Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)","volume":"47","author":"Ohlsson","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2014.08.008_bb0515","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0520","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","article-title":"Anakinra for systemic juvenile arthritis: the Rocky Mountain experience","volume":"15","author":"Zeft","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0525","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0530","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0535","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0540","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RHU.0b013e31812e00a1","article-title":"Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)","volume":"13","author":"Settas","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0545","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1475-2840-13-94","article-title":"Safety and tolerability of canakinumab, an IL-1\u03b2 inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies","volume":"13","author":"Howard","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0550","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study","volume":"8","author":"Sundy","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.008_bb0555","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.08.008_bb0560","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.008_bb0565","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0570","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","article-title":"Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study","volume":"34","author":"Hoffman","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2014.08.008_bb0575","first-page":"1","article-title":"Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)","volume":"3","author":"Gillespie","year":"2010","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.autrev.2014.08.008_bb0580","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/art.23620","article-title":"A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome","volume":"58","author":"Goldbach-Mansky","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0585","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.008_bb0590","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2014.08.008_bb0595","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.autrev.2004.09.001","article-title":"Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases","volume":"4","author":"Botsios","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.008_bb0600","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/ng0902-97","article-title":"Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae","volume":"32","author":"Ottenhoff","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2014.08.008_bb0605","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.4049\/jimmunol.175.12.8200","article-title":"CD11b+\/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells","volume":"175","author":"Song","year":"2005","journal-title":"J Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T10:56:34Z","timestamp":1538304994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214001529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1568997214001529"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.008","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}